Measures for the Prevention of Mother-to-Child Human T-Cell Leukemia Virus Type 1 Transmission in Japan: The Burdens of HTLV-1-Infected Mothers.
exclusive formula feeding
human T-cell leukemia virus
mother-to-child transmission
short-term breastfeeding
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
26 09 2023
26 09 2023
Historique:
received:
11
09
2023
revised:
24
09
2023
accepted:
25
09
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The main mode of mother-to-child transmission of the human T-cell leukemia virus (HTLV)-1 is through breastfeeding. Although the most reliable nutritional regimen to prevent HTLV-1 transmission is exclusive formula feeding, a recent meta-analysis revealed that short-term breastfeeding within 90 days does not increase the risk of infection. The protocol of the Japanese Health, Labor, and Welfare Science Research Group primarily recommended exclusive formula feeding for mothers who are positive for HTLV-1. However, there has been no quantitative research on the difficulties experienced by HTLV-1-positive mothers in carrying out these nutritional regimens, including the psychological burden. Therefore, this review was performed to clarify the burdens and difficulties encountered by mothers who are positive for HTLV-1; to this end, we analyzed the data registrants on the HTLV-1 career registration website "Carri-net" website. The data strongly suggest that it is not sufficient to simply recommend exclusive formula feeding or short-term breastfeeding as a means of preventing mother-to-child transmission; it is important for health care providers to understand that these nutritional regimens represent a major burden for pregnant women who are positive for HTLV-1 and to provide close support to ensure these women's health.
Identifiants
pubmed: 37896779
pii: v15102002
doi: 10.3390/v15102002
pmc: PMC10610977
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Med Virol. 2023 Mar;95(3):e28606
pubmed: 36815496
Front Microbiol. 2012 Jul 24;3:270
pubmed: 22837757
J Hum Virol. 1997 Nov-Dec;1(1):37-44
pubmed: 10195229
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S8-14
pubmed: 8797697
Lancet Infect Dis. 2019 Jan;19(1):15-16
pubmed: 30587282
Jpn J Cancer Res. 1985 Jun;76(6):474-80
pubmed: 2991060
Breastfeed Rev. 2002 Nov;10(3):5-18
pubmed: 12592775
Front Microbiol. 2012 Nov 09;3:389
pubmed: 23162542
Pediatr Int. 2014 Aug;56(4):640-3
pubmed: 25252059
Cancer Sci. 2020 Dec;111(12):4567-4580
pubmed: 32976684
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(4):152-66
pubmed: 21558754
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S199-203
pubmed: 8797724
Blood. 2017 Mar 2;129(9):1071-1081
pubmed: 28115366
BMC Public Health. 2020 Jul 22;20(1):1150
pubmed: 32698800
JAMA. 2014 Oct 1;312(13):1295-6
pubmed: 25268434
Pediatr Infect Dis J. 2013 Feb;32(2):175-7
pubmed: 23328821
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Front Microbiol. 2012 Sep 10;3:322
pubmed: 22973265
Front Microbiol. 2020 Apr 09;11:595
pubmed: 32328047
Viruses. 2021 May 01;13(5):
pubmed: 34062915
Lancet Infect Dis. 2016 Nov;16(11):1246-1254
pubmed: 27567105
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208
Oncogene. 2003 Aug 11;22(33):5131-40
pubmed: 12910250
Front Microbiol. 2020 May 29;11:1124
pubmed: 32547527
Cancers (Basel). 2021 Aug 14;13(16):
pubmed: 34439253